XNW3009 / Evopoint - LARVOL DELTA

To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: The Affiliated Hospital of Qingdao University | Trial primary completion date: Apr 2022 ➔ Aug 2022

Trial primary completion date • Gout • Inflammatory Arthritis • Rheumatology

To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: The Affiliated Hospital of Qingdao University

New P1 trial • Gout • Inflammatory Arthritis • Rheumatology

The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject (clinicaltrials.gov) - P1; N=40; Completed; Sponsor: Sinovent Pty Ltd.; Recruiting ➔ Completed; N=72 ➔ 40

Clinical • Enrollment change • Trial completion • Gout • Inflammatory Arthritis • Rheumatology

The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: Sinovent Pty Ltd.; Trial completion date: Oct 2020 ➔ May 2021; Trial primary completion date: Aug 2020 ➔ Jan 2021

Clinical • Trial completion date • Trial primary completion date • Gout • Inflammatory Arthritis • Rheumatology

The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: Sinovent Pty Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Newly added product (clinicaltrials.gov) - P1, Inflammation

Pipeline update

The the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XNW3009 in Health Subject (clinicaltrials.gov) - P1; N=72; Not yet recruiting; Sponsor: Sinovent Pty Ltd.

Clinical • New P1 trial